These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36849497)

  • 1. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
    Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G
    Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
    Jodele S; Licht C; Goebel J; Dixon BP; Zhang K; Sivakumaran TA; Davies SM; Pluthero FG; Lu L; Laskin BL
    Blood; 2013 Sep; 122(12):2003-7. PubMed ID: 23814021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
    Catanese L; Link K; Rupprecht H
    BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.
    Gavriilaki E; Dalampira D; Theodorakakou F; Liacos CI; Kanellias N; Eleutherakis-Papaiakovou E; Terpos E; Gavriatopoulou M; Verrou E; Triantafyllou T; Sevastoudi A; Koravou EE; Touloumenidou T; Varelas C; Papalexandri A; Sakellari I; Dimopoulos MA; Kastritis E; Katodritou E
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Attucci I; Pilerci S; Messeri M; Pengue L; Tomasino G; Caroti L; Vannucchi AM; Antonioli E
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e2163. PubMed ID: 39390755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
    Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
    BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
    Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
    Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
    Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
    J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
    Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
    Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
    Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
    Fang W; Sun W; Fang W; Zhao S; Wang C
    Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics and genetic profile of complement system in renal thrombotic microangiopathy in patients with severe forms of arterial hypertension].
    Akaeva MI; Kozlovskaya NL; Bobrova LA; Vorobyeva OA; Stoliarevich ES; Shatalov PA; Smirnova TV; Anan'eva AO
    Ter Arkh; 2024 Jul; 96(6):571-579. PubMed ID: 39106497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of thrombotic microangiopathies in multiple myeloma.
    Portuguese AJ; Gleber C; Passero FC; Lipe B
    Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
    Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.
    Che M; Moran SM; Smith RJ; Ren KYM; Smith GN; Shamseddin MK; Avila-Casado C; Garland JS
    Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.
    Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K
    Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
    Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
    Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.